In the entire history of cannabis medicine, one application has cleared every evidentiary bar that mainstream medicine demands: cannabidiol for treatment-resistant epilepsy. It has randomized controlled trials. It has FDA approval. It has a specific, named pharmaceutical product — Epidiolex — prescribed by neurologists in conventional clinical settings. It has published five-year safety data.

No other cannabinoid-based therapy comes close to this level of validation. The story of how CBD went from fringe alternative treatment to FDA-approved medication is the most important story in medical cannabis, and it carries implications far beyond epilepsy.

Charlotte Figi and the Beginning

The modern CBD-for-epilepsy movement began with a single patient: Charlotte Figi, born in October 2006 in Colorado Springs, Colorado. Charlotte was diagnosed with Dravet syndrome, a rare and catastrophic form of epilepsy caused by mutations in the SCN1A gene. Dravet syndrome typically manifests in the first year of life and produces severe, prolonged seizures that are resistant to nearly all conventional anticonvulsant medications.

By age five, Charlotte was experiencing approximately 300 grand mal seizures per week. Her parents had tried every available anticonvulsant medication, the ketogenic diet, and vagus nerve stimulation. Nothing provided sustained relief. Her cognitive development was severely impaired, she had lost the ability to walk and speak, and her physicians had exhausted all options.

In 2012, Charlotte’s parents connected with the Stanley Brothers, a group of Colorado cannabis cultivators who had developed a high-CBD, low-THC cannabis strain. The strain — later named Charlotte’s Web — contained approximately 17% CBD and less than 0.3% THC. Charlotte began receiving a CBD-rich oil extract.

Her seizures dropped from 300 per week to two to three per month. She regained the ability to walk, eat, and engage with her environment. The transformation was documented in a 2013 CNN documentary by Dr. Sanjay Gupta, which introduced millions of Americans to the concept of medical CBD and is widely credited with shifting public opinion on cannabis medicine.

Charlotte Figi died in April 2020 at age 13, from complications believed to be related to COVID-19. She remains the most recognized name in the medical cannabis movement and the patient whose case catalyzed a pharmaceutical development program that would ultimately change federal drug policy.

The Mechanism: How CBD Reduces Seizures

CBD’s anticonvulsant mechanism is distinct from its other pharmacological effects and has been progressively elucidated through preclinical research.

Unlike THC, CBD does not act primarily through CB1 or CB2 cannabinoid receptors. Its anticonvulsant activity appears to involve multiple molecular targets working in concert:

GPR55 antagonism. CBD blocks the GPR55 receptor, sometimes called the “orphan cannabinoid receptor.” GPR55 activation increases intracellular calcium release and neuronal excitability. By blocking GPR55 in the hippocampus, CBD reduces the excitatory signaling that propagates seizure activity. A 2018 study in the Proceedings of the National Academy of Sciences identified GPR55 antagonism as a primary mechanism by demonstrating that CBD’s anticonvulsant effects were abolished in GPR55 knockout mice.

TRPV1 channel modulation. CBD activates transient receptor potential vanilloid type 1 (TRPV1) channels, which, upon sustained activation, desensitize and reduce neuronal excitability. This contributes to CBD’s ability to dampen the hyperexcitable neural circuits that generate seizures.

Sodium channel blockade. At therapeutic concentrations, CBD inhibits voltage-gated sodium channels (particularly Nav1.6), reducing the rapid sodium influx that drives action potential firing in epileptic neurons. This mechanism is shared with several conventional anticonvulsants, including carbamazepine and phenytoin.

Adenosine reuptake inhibition. CBD inhibits the equilibrative nucleoside transporter (ENT1), which reabsorbs adenosine from the extracellular space. By increasing extracellular adenosine concentrations, CBD enhances the natural inhibitory signaling that adenosine provides throughout the brain.

This multi-target mechanism may explain why CBD is effective in treatment-resistant epilepsy — patients whose seizures are not controlled by drugs targeting any single mechanism may respond to a compound that modulates several mechanisms simultaneously.

The Clinical Trials

GW Pharmaceuticals (now part of Jazz Pharmaceuticals) developed Epidiolex, a purified pharmaceutical-grade CBD oral solution, and conducted the clinical trial program required for FDA approval. The trials were rigorous, large-scale, and produced unambiguous results.

Dravet syndrome trials. The first pivotal Phase III trial, published in the New England Journal of Medicine in May 2017, randomized 120 children and young adults with Dravet syndrome to Epidiolex (20 mg/kg/day) or placebo for 14 weeks. The primary endpoint was median change in monthly convulsive seizure frequency.

The Epidiolex group experienced a median 38.9% reduction in convulsive seizures, compared to 13.3% in the placebo group — a statistically significant and clinically meaningful difference (p = 0.01). Notably, 5% of patients in the CBD group became completely seizure-free during the treatment period, compared to 0% in the placebo group.

A second Dravet syndrome trial, published in the New England Journal of Medicine in 2018, tested two doses (10 mg/kg/day and 20 mg/kg/day) against placebo in 199 patients. Both doses significantly reduced seizure frequency, with the 20 mg/kg dose producing a 45.7% reduction versus 26.9% for placebo.

Lennox-Gastaut syndrome trials. Lennox-Gastaut syndrome (LGS) is another severe childhood-onset epilepsy characterized by multiple seizure types, cognitive impairment, and extreme treatment resistance. Two Phase III trials of Epidiolex in LGS were published in the New England Journal of Medicine and The Lancet in 2018.

The first LGS trial randomized 225 patients to Epidiolex (20 mg/kg/day) or placebo. Drop seizures — the most dangerous seizure type in LGS, causing sudden falls and injury — decreased by 43.9% in the CBD group versus 21.8% for placebo (p = 0.0135).

The second LGS trial tested both 10 mg/kg/day and 20 mg/kg/day against placebo in 171 patients, with similar results. Both doses significantly outperformed placebo, and the results were consistent across age groups, concomitant medications, and baseline seizure severity.

Tuberous sclerosis complex. In 2020, GW Pharmaceuticals published Phase III results for Epidiolex in tuberous sclerosis complex (TSC)-associated epilepsy, another genetic condition producing treatment-resistant seizures. The trial randomized 224 patients to CBD (25 mg/kg/day or 50 mg/kg/day) or placebo. Both CBD doses produced statistically significant seizure reductions versus placebo, leading to an expanded FDA indication in 2020.

FDA Approval and DEA Rescheduling

On June 25, 2018, the FDA approved Epidiolex for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older. It was the first FDA-approved medication derived from cannabis.

The approval created an immediate legal paradox. Cannabis was a Schedule I substance — defined as having “no currently accepted medical use.” The FDA had just accepted a medical use. The DEA was forced to act: in September 2018, it placed Epidiolex in Schedule V, the least restrictive controlled substance category, while cannabis itself remained in Schedule I. This was the first time any cannabis-derived substance had been officially rescheduled.

In April 2020, the DEA went further and removed Epidiolex from the controlled substances schedule entirely, making it the first cannabis-derived medication to be fully descheduled. The rationale: Epidiolex contains less than 0.1% THC and has no abuse potential.

The broader political significance cannot be overstated. The FDA approval of Epidiolex permanently demolished the argument that cannabis has “no accepted medical use.” When DEA judges and Congressional opponents of cannabis reform repeat this talking point, the existence of Epidiolex is an irrefutable counterexample. This single approval has been cited in multiple federal rescheduling petitions and played a role in the HHS recommendation to move cannabis to Schedule III.

Long-Term Safety Data

One of the most important aspects of the Epidiolex story is the long-term safety data that has accumulated since approval. Open-label extension studies have now followed patients on continuous CBD therapy for up to five years.

The most commonly reported side effects in clinical trials were somnolence (drowsiness), decreased appetite, diarrhea, and elevated liver enzymes. The liver enzyme elevations occurred primarily in patients taking concomitant valproate (another anticonvulsant) and were dose-dependent and reversible with dose adjustment or valproate discontinuation. Regular liver function monitoring is recommended during treatment.

The five-year extension data, published in Epilepsia in 2023, found that CBD maintained its efficacy over time without evidence of tolerance — patients did not need increasing doses to maintain seizure control. This is significant because tolerance is a major problem with many conventional anticonvulsants, particularly benzodiazepines.

Importantly, no evidence of cognitive impairment, addiction, withdrawal, or abuse has emerged in the long-term data. Unlike THC-containing products, CBD does not produce euphoria, does not impair cognition at therapeutic doses, and has no identified abuse potential. This safety profile is one of the cleanest in the anticonvulsant class.

Beyond Epidiolex: The Broader Landscape

Epidiolex is a purified, pharmaceutical-grade CBD product — it is not the same as the CBD oils, capsules, and tinctures sold in dispensaries, health food stores, and gas stations. Over-the-counter CBD products are not FDA-approved for epilepsy or any other condition, are not subject to pharmaceutical manufacturing standards, and vary widely in actual CBD content.

A 2017 study published in JAMA found that only 31% of commercial CBD products contained the amount of CBD listed on the label, with significant numbers containing less CBD than advertised, more CBD than advertised, or detectable THC not declared on the label. For a parent considering CBD for a child with epilepsy, this variability is not a minor quality concern — it is a potential safety issue.

That said, many families use non-pharmaceutical CBD products for epilepsy management, particularly Charlotte’s Web and similar whole-plant extracts. Some clinicians and families report that whole-plant CBD extracts produce better seizure control at lower doses than purified CBD, potentially due to the entourage effect — the synergistic interaction between CBD and other cannabis compounds (minor cannabinoids, terpenes, flavonoids). A 2018 meta-analysis in Frontiers in Neurology found that CBD-rich extracts were associated with lower effective doses and fewer side effects than purified CBD, though the analysis was based on observational data, not controlled trials.

What the Epilepsy Story Means for Cannabis Medicine

The CBD-for-epilepsy story matters beyond epilepsy for several reasons.

First, it demonstrates that cannabinoids can survive the most rigorous scrutiny pharmaceutical regulation demands. The argument that “cannabis can’t be medicine because it hasn’t been tested properly” was always circular — the Schedule I classification prevented the testing. When researchers were finally permitted to conduct proper trials, the results were unambiguous.

Second, it provides a template. The Epidiolex development pathway shows that cannabis-derived compounds can move through the FDA process, achieve approval, and reach patients through conventional medical channels. Other cannabinoid-based medications — for pain, anxiety, PTSD, and other conditions — can follow the same pathway as federal research restrictions continue to loosen.

Third, it forces honesty in both directions. CBD advocates who claim that CBD cures everything should look at the epilepsy data honestly: CBD works exceptionally well for specific conditions at specific doses, but the clinical evidence for most other claimed benefits remains preliminary. Cannabis opponents who claim cannabinoids have no medical value should look at the same data: the Phase III trials are clear, the FDA approval is real, and the long-term safety data is reassuring.

Charlotte Figi’s legacy is not just the lives saved by Epidiolex. It is the proof of concept that cannabis compounds, subjected to proper scientific investigation, can produce outcomes that reshape medicine and policy. The most rigorously tested cannabinoid application turned out to be one of the most effective. That is not a coincidence.